We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Oxurion NV (OXUR) Ord

Sell:€1.88 Buy:€1.90 Change: €0.006 (0.32%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: €0.006 (0.32%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: €0.006 (0.32%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.

Contact details

Gaston Geenslaan 1
+32 (16) 751310

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€73.61 million
Shares in issue:
38.86 million
Euronext Brussels

Key personnel

  • Tom Graney
    Chief Executive Officer, Chief Financial Officer
  • Julie Binon
    Chief People Officer, Member of the Executive Committee
  • Alan Stitt
    Chief Scientific Officer, Member of the Executive Committee
  • Kathleen Paisley
    Chief Legal Officer and General Counsel, Member of the Executive Committee
  • Michael Dillen
    Chief Corporate Development Officer, Company Secretary, Member of the Executive Committee,
  • Grace Chang
    Chief Medical Officer, Member of the Executive Committee
  • Andy De Deene
    Chief Development Officer, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.